基础胰岛素周制剂的研发与临床研究进展  

Development and Clinical Research Progress of Basic Insulin Weekly Preparation

作　　者：郭立新[1] GUO Lixin(National Center of Gerontology,Beijing Hospital,Beijing 100730,China)

机构地区：[1]北京医院国家老年医学中心,北京100730

出　　处：《药品评价》2022年第12期705-707,720,共4页Drug Evaluation

摘　　要：胰岛素在血糖管理中占有重要地位,及时起始外源性胰岛素补充治疗是非常必要的手段,但目前胰岛素为日制剂,需要每天注射至少1次,多则2~4次,可能还需结合口服降糖药物,这意味着复杂的治疗策略和自我血糖管理。每周只需注射一次的胰岛素也许会大大简化用药方案,减轻医患双方的负担。本文从分析基础胰岛素的作用、未被满足的临床现状等方面来探讨新近基础胰岛素周制剂的新进展。Insulin plays an important role in blood glucose management,timely initiating exogenous insulin therapy is a very necessary means for a large part of patients with type 2 diabetes.However,most of insulin products are administered as daily preparations nowadays,which need to be injected at least once a day or even as many as 2 to 4 times a day,with combination of oral antihyerglycemic drugs sometimes,which implies complex treatment strategies and the need of self-management of blood glucose.A once-weekly injection of insulin may greatly simplify the medication regimen and reduce the burden of both physicians and patients.This article will discuss the new progress of the once-weekly basal insulin preparations by reviewing the effects of basal insulin and the unmet clinical status.

关 键 词：糖尿病 2型 迟效制剂 基础胰岛素 胰岛素周制剂 

分 类 号：R943[医药卫生—药剂学]